Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome
Overview
Authors
Affiliations
To understand and treat immunology-related diseases, a comprehensive, unbiased characterization of major histocompatibility complex (MHC) peptide ligands is of key importance. Preceding the analysis by mass spectrometry, MHC class I peptide ligands are typically isolated by MHC immunoaffinity chromatography (MHC-IAC) and less often by mild acid elution (MAE). MAE may provide a cheap alternative to MHC-IAC for suspension cells but has been hampered by the high number of contaminating, MHC-unrelated peptides. Here, we optimized MAE, yielding MHC peptide ligand purities of more than 80%. When compared with MHC-IAC, obtained peptides were similar in numbers, identities, and to a large extent intensities, while the percentage of cysteinylated peptides was 5 times higher in MAE. The latter benefitted the discovery of MHC-allotype-specific, distinct cysteinylation frequencies at individual positions of MHC peptide ligands. MAE revealed many MHC ligands with unmodified, N-terminal cysteine residues which get lost in MHC-IAC workflows. The results support the idea that MAE might be particularly valuable for the high-confidence analysis of post-translational modifications by avoiding the exposure of the investigated peptides to enzymes and reactive molecules in the cell lysate. Our improved and carefully documented MAE workflow represents a high-quality, cost-effective alternative to MHC-IAC for suspension cells.
Balakrishnan A, Winiarek G, Holowka O, Godlewski J, Bronisz A Front Immunol. 2025; 16:1540431.
PMID: 39944685 PMC: 11814183. DOI: 10.3389/fimmu.2025.1540431.
Crucial Parameters for Immunopeptidome Characterization: A Systematic Evaluation.
Juanes-Velasco P, Arias-Hidalgo C, Garcia-Vaquero M, Sotolongo-Ravelo J, Paino T, Lecrevisse Q Int J Mol Sci. 2024; 25(17).
PMID: 39273511 PMC: 11395153. DOI: 10.3390/ijms25179564.
Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens.
Hesnard L, Theriault C, Cahuzac M, Durette C, Vincent K, Hardy M Curr Oncol. 2024; 31(6):3099-3121.
PMID: 38920720 PMC: 11203340. DOI: 10.3390/curroncol31060236.
Larson A, Knoche S, Brumfield G, Doty K, Gephart B, Moore-Saufley P Int J Mol Sci. 2024; 25(6).
PMID: 38542184 PMC: 10970070. DOI: 10.3390/ijms25063211.
COSMIC-based mutation database enhances identification efficiency of HLA-I immunopeptidome.
Wang F, Zhang Z, Mao M, Yang Y, Xu P, Lu S J Transl Med. 2024; 22(1):144.
PMID: 38336780 PMC: 10858511. DOI: 10.1186/s12967-023-04821-0.